Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCAR-T 2019 | Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts

David Maloney, John Gribben and Saar Gill • 11 Oct 2019
iwCAR-T 2019
Acute Myeloid Leukemia Leukemia Multiple Myeloma CAR-T

John Gribben, MD, DSc , FRCPath, FMed Sci, Barts Cancer Institute, London, UK, is joined by Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, to share their highlights from day 2 of the 1st International Workshop on CAR-T (iwCAR-T), held in Miami, FL. The speakers discuss difficulties in targeting acute myeloid leukemia (AML), CAR T-cell therapy in multiple myeloma and clinical trial regulations in China. Allogeneic CAR-Ts are also touched upon.

More from David Maloney

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
4:36
Highlights from the immunotherapy in CLL session
David Maloney • 20 Sep 2021

More from John Gribben

2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Saar Gill

16:12
Exploring the potential of CAR-T therapy in CLL
John Gribben et al. • 30 Apr 2022
25:18
Addressing the major challenges to CAR-T therapy in AML
John DiPersio et al. • 30 Apr 2022
13:25
CLL and CAR-T
Jordan Gauthier et al. • 11 Oct 2019
1:48
Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS
Saar Gill • 15 Jan 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals